-
1Academic Journal
Συγγραφείς: B. Ya. Alekseev, V. M. Perepukhov, K. M. Nyushko, M. G. Poltavskaya, Б. Я. Алексеев, В. М. Перепухов, К. М. Нюшко, М. Г. Полтавская
Πηγή: Cancer Urology; Том 20, № 3 (2024); 80-93 ; Онкоурология; Том 20, № 3 (2024); 80-93 ; 1996-1812 ; 1726-9776
Θεματικοί όροι: лейпрорелин, overall survival, androgen deprivation therapy, cardiovascular complication, luteinizing hormone-releasing hormone agonist, luteinizing hormone-releasing hormone antagonist, leuprorelin, общая выживаемость, андрогендепривационная терапия, сердечно-сосудистое осложнение, агонист лютеинизирующего гормона рилизинг-гормона, антагонист лютеинизирующего гормона рилизинг-гормона
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1876/1559; Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49. DOI:10.3322/caac.21660; Состояние онкологической помощи населению России в 2023 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. 262 с.; Рак предстательной железы. Клинические рекомендации. Минздрав РФ, 2021.; Jonušas J., Drevinskaitė М., Patašius А. et al. Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study. Aging Male 2022;25(1):173–9. DOI:10.1080/13685538.2022.2091130; Keating N.L., O’Malley A.J., Freedland S.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102(1):39–46. DOI:10.1093/jnci/djp404; Saigal C.S., Gore J.L., Krupski T.L. et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110(7):1493–500. DOI:10.1002/cncr.22933; Van Hemelrijck M., Garmo H., Holmberg L. et al. Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden. Eur Urol 2012;61(4):690–700. DOI:10.1016/j.eururo.2011.09.010; GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392(10159):1736–88. DOI:10.1016/S0140-6736(18)32203-7; Mensah G.A., Fuster V., Murray C.J.L. et al. Global burden of cardiovascular diseases and risks, 1990–2022. J Am Coll Cardiol 2023;82(25):2350–473. DOI:10.1016/j.jacc.2023.11.007; Armenian S.H., Xu L., Ky B. et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 2016;34(10):1122–30. DOI:10.1200/JCO.2015.64.0409; Mulrooney D.A., Yeazel M.W., Kawashima T. et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606. DOI:10.1136/bmj.b4606; Haugnes H.S., Wethal T., Aass N. et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010;28(30):4649–57. DOI:10.1200/JCO.2010.29.9362; Lenihan D.J., Cardinale D.M. Late cardiac effects of cancer treatment. J Clin Oncol 2012;30(30):3657–64. DOI:10.1200/JCO.2012.45.2938; Coleman M.P., Gatta G., Verdecchia A. et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003;14:v128–49. DOI:10.1093/annonc/mdg756; Sturgeon K.M., Deng L., Bluethmann S.M. et al. A populationbased study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019;40(48):3889–97. DOI:10.1093/eurheartj/ehz766; Leong D.P., Fradet V., Shayegan B. et al. Cardio-vascular risk in men with prostate cancer: insights from the RADICAL PC study. J Urol 2020;203(6):1109–16. DOI:10.1097/JU.0000000000000714; Smith M.R., Klotz L., van der Meulen E. et al. Gonadotropinreleasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol 2011;186(5):1835–42. DOI:10.1016/j.juro.2011.07.035; Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. Cancer J Clin 2022;72(1):7–33. DOI:10.3322/caac.21708; Klimis H., Pinthus J.H., Aghel N. et al. The burden of uncontrolled cardiovascular risk factors in men with prostate cancer: a RADICAL-PC analysis. JACC CardioOncol 2023;5(1):70–81. DOI:10.1016/j.jaccao.2022.09.008; Goodale T., Sadhu A., Petak S., Robbins R. Testosterone and the heart. Methodist Debakey Cardiovasc J 2017;13(2):68–72. DOI:10.14797/mdcj-13-2-68; Brouillette J., Rivard K., Lizotte E., Fiset C. Sex and strain differences in adult mouse cardiac repolarization: importance of androgens. Cardiovasc Res 2005;65(1):148–57. DOI:10.1016/j.cardiores.2004.09.012; Tsang S., Wu S., Liu J., Wong T.M. Testosterone protects rat hearts against ischaemic insults by enhancing the effects of α1-adrenoceptor stimulation. Br J Pharmacol 2008;153(4): 693–709. DOI:10.1038/sj.bjp.0707624; Campelo A.E., Cutini P.H., Massheimer V.L. Testosterone modulates platelet aggregation and endothelial cell growth through nitric oxide pathway. J Endocrinol 2012;213(1):77–87. DOI:10.1530/JOE-11-0441; Scragg J.L., Jones R.D., Channer K.S. et al. Testosterone is a potent inhibitor of L-type Ca2+ channels. Biochem Biophys Res Commun 2004;318(2):503–6. DOI:10.1016/j.bbrc.2004.04.054; Tzortzis V., Samarinas M., Zachos I. et al. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications. Hormones 2017;16(2):115–23. DOI:10.14310/horm.2002.1727; Panagiotis M.I., Papatsoris A.G., Siasos G. et al. The effect of androgen deprivation therapy in arterial stiffness of the aorta and the endothelial function of peripheral arteries. Urol Nephrol Open Access J 2014;1(2):42–5.; Hopmans S.N., Duivenvoorden W.C., Werstuck G.H. et al. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol 2014;32(8):1126–34. DOI:10.1016/j.urolonc.2014.06.018; Poljak Z., Hulin I., Maruscakova L., Mladosievicova B. Are GnRH and FSH potentially damaging factors in the cardiovascular system? Pharmazie 2018;73(4):187–90. DOI:10.1691/ph.2018.7992; Crawford E.D., Schally A.V., Pinthus J.H. et al. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol 2017;35(5):183–91. DOI:10.1016/j.urolonc.2017.01.025; Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl 2008;29(5):534–9. DOI:10.2164/jandrol.108.005454; Wang T., Li M., Zeng T. et al. Association between insulin resistance and cardiovascular disease risk varies according to glucose tolerance status: a nationwide prospective cohort study. Diabetes Care 2022;45(8):1863–72. DOI:10.2337/dc22-0202; Herink M., Ito M.K. Medication induced changes in lipid and lipoproteins. Eds.: K.R. Feingold, B. Anawalt, M.R. Blackman et al. Endotext. MDText.com, Inc, 2000.; Pol T., Held C., Westerbergh J. et al. Dyslipidemia and risk of cardiovascular events in patients with atrial fibrillation treated with oral anticoagulation therapy: insights from the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial. J Am Heart Assoc 2018;7(3):e007444. DOI:10.1161/JAHA.117.007444; Katsoulis M., Stavola B.D., Diaz-Ordaz K. et al. Weight change and the onset of cardiovascular diseases: emulating trials using electronic health records. Epidemiology 2021;32(5):744–55. DOI:10.1097/EDE.0000000000001393; Seible D.M., Gu X., Hyatt A., Beard C. Identifying men at greatest risk of weight gain from androgen deprivation therapy. J Clin Oncol 2014;32(4_suppl):80. DOI:10.1200/jco.2014.32.4_suppl.80; Nelson A.J., Lopes R.D., Hong H. et al. Cardiovascular effects of GnRH antagonists compared with agonists in prostate cancer: a systematic review. JACC CardioOncol 2023;5(5):613–24. DOI:10.1016/j.jaccao.2023.05.011; Cicione A., Nacchia A., Guercio A. et al. Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries. Prostate Cancer Prostatic Dis 2023;26(4):765–71. DOI:10.1038/s41391-022-00640-4; Lopes R.D., Higano C.S., Slovin S.F. et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation 2021;144(16):1295–307. DOI:10.1161/CIRCULATIONAHA.121.056810; Kokorovic A., So A.I., Serag H. et al. UPDATE–Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. Can Urol Assoc J 2022;16(8): E416–31. DOI:10.5489/cuaj.8054; Crawford E.D., Hafron J.M., Debruyne F. et al. Cardiovascular risk in prostate cancer patients using luteinizing hormone-releasing hormone agonists or a gonadotropin-releasing hormone antagonist. J Urol 2024;211(1):63–70. DOI:10.1097/JU.0000000000003721; Crawford E.D., Hafron J.M., Tagawa S.T. et al. Impact of late dosing on testosterone suppression with 2 different leuprolide acetate formulations: in situ gel and microsphere. An Analysis of United States Clinical Data. J Urol 2021;205(2):554–60. DOI:10.1097/JU.0000000000001392; Patel S., Zhu K., Dav C.V. et al. Comparative cardiovascular safety of gonadotropin-releasing hormone antagonists and agonists among patients diagnosed with prostate cancer: a systematic review and meta-analysis of real-world evidence studies. Eur Urol Oncol 2024;S2588-9311(24)00213-X. DOI:10.1016/j.euo.2024.09.004; Okada H. One-and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev 1997;28(1):43–70. DOI:10.1016/s0169-409x(97)00050-1; Fujino M., Fukuda T., Shinagawa S. et al. Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10. Biochem Biophys Res Commun 1974;60(1): 406–13. DOI:10.1016/0006-291x(74)90219-8; Abouelfadel Z., Crawford E.D. Leuprorelin depot injection: patient considerations in the management of prostatic cancer. Ther Clin Risk Manag 2008;4(2):513–26. DOI:10.2147/tcrm.s686; Özyi̇ği̇t G., Akyol F. Cost-effectiveness analysis of leuprorelin acetate atrigel in the treatment of prostate cancer. Turkish Journal of Oncology 2020;35(4):430–7. DOI:10.5505/tjo.2020.2449; The European Medicines. Available at: Agencyhttps://www.ema.europa.eu/en/medicines/human/referrals/leuprorelin-containing-depotmedicinal-products; Tombal B., Berges R. How good do current LHRH agonists control testosterone? Can this be improved with Eligard®? Eur Urol Suppl 2005; 4(8):30–6. DOI:10.1016/J.EURSUP.2005.08.004; Dadey E.J. The atrigel drug delivery system. Modified-release drug delivery technology. CRC Press, 2008. Pp. 211–218.; Kempe S., Mäder K. In situ forming implants – an attractive formulation principle for parenteral depot formulations. J Control Release 2012;161(2):668–79. DOI:10.1016/j.jconrel.2012.04.016; Shimoyama M., Murata Y., Sumi K. et al. Docetaxel induced cardiotoxicity. Heart 2001;86:219. DOI:10.1136/heart.86.2.219; Bendahou H., Ettagmouti Y., Abouriche A. et al. Cardiotoxicity due to docetaxel rare but it exists: about a case and literature review. J Case Rep Med Hist 2023;3(1). DOI:10.54289/JCRMH2300105; Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187–97. DOI:10.1056/NEJMoa1207506; Beer T.M., Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424–33. DOI:10.1056/NEJMc1410239; Davis I.D., Martin A.J., Stockler M.R. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381(2):121–31. DOI:10.1056/NEJMoa1903835; Hussain M., Fizazi K., Saad F. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378(26):2465–74. DOI:10.1056/NEJMoa1800536; Salem J.E., Yang T., Moslehi J.J. et al. Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 2019;140(13): 1070–80. DOI:10.1161/CIRCULATIONAHA.119.040162; Smith M.R., Saad F., Chowdhury S. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378(15):1408–18. DOI:10.1056/NEJMoa1715546; Chi K.N., Agarwal N., Bjartell A. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381(1):13–24. DOI:10.1056/NEJMoa1903307; Fizazi K., Shore N., Tammela T.L. et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380(13):1235–46. DOI:10.1056/NEJMoa1815671; Smith M.R., Hussain M., Saad F. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386(12):1132–42. DOI:10.1056/NEJMoa2119115; O'Donnell A., Judson I., Dowsett M. et al. Hormonal impact of the 17α-hydroxylase/C17, 20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90(12):2317–25. DOI:10.1038/sj.bjc.6601879; Attard G., Reid A.H.M., Auchus R.J. et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012;97(2):507–16. DOI:10.1210/jc.2011-2189; De Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995–2005. DOI:10.1056/NEJMoa1014618; Ryan C.J., Smith M.R., de Bono J.S. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138–48. DOI:10.1056/NEJMoa1209096; Fizazi K., Tran N.P., Fein L. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352–60. DOI:10.1056/NEJMoa1704174; Zhu X., Wu S. Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis. Clin Hypertens 2019;25:1–9. DOI:10.1186/s40885-019-0110-3; Salem J.E., Alexandre J., Bachelot A., Funck-Brentano C. Influence of steroid hormones on ventricular repolarization. Pharmacol Ther 2016;167:38–47. DOI:10.1016/j.pharmthera.2016.07.005; Iacovelli R., Ciccarese C., Bria E. et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer 2018;16(3):e645–53. DOI:10.1016/j.clgc.2017.12.007; Lu-Yao G., Nikita N., Keith S.W. et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol 2020;77(2):158–66. DOI:10.1016/j.eururo.2019.07.031; Verzoni E., Grassi P., Ratta R. et al. Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. Ther Adv Med Oncol 2016;8(5):323–30. DOI:10.1177/1758834016656493; Lyon A.R., López-Fernández T., Couch L.S. et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J 2022;23(10):e333–465. DOI:10.1093/eurheartj/ehac244; Бойцов С.А., Погосова Н.В., Аншелес А.А. и др. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал 2023;28(5):5452. DOI:10.15829/1560-4071-2023-5452; Виценя М.В., Агеев Ф.Т., Орлова Р.В. и др. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2023;13(#3s2):86–111.; Visseren F.L.J., Mach F., Smulders Y.M. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2021;42(34):3227–37.; Okwuosa T.M., Morgans A., Rhee J.W. et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med 2021;14(3):e000082. DOI:10.1161/HCG.0000000000000082; Wilk M., Waśko-Grabowska A., Skoneczna I., Szmit S. Angiotensin system inhibitors may improve outcomes of patients with castrationresistant prostate cancer during abiraterone acetate treatment— a cardio-oncology study. Front Oncol 2021;11:664741. DOI:10.3389/fonc.2021.664741; Salem J.E., Waintraub X., Courtillot C. et al. Hypogonadism as a reversible cause of torsades de pointes in men. Circulation 2018;138(1):110–3. DOI:10.1161/CIRCULATIONAHA.118.034282; Crawford E.D., Garnick M.B., Eckel R.H. et al. A proposal for the comprehensive care of men on androgen deprivation therapy: recommendations from the multidisciplinary Prostate Cancer 360 Working Group. Urol Pract 2024;11(1):18–29. DOI:10.1097/UPJ.0000000000000473; Goff Jr D.C., Lloyd-Jones D.M., Bennett G. et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 suppl 2):S49–73. DOI:10.1161/01.cir.0000437741.48606.98; Jayalath V.H., Clark R., Lajkosz K. et al. Statin use and survival among men receiving androgen-ablative therapies for advanced prostate cancer: a systematic review and meta-analysis. JAMA Netw Open 2022;5(11):e2242676. DOI:10.1001/jamanetworkopen.2022.42676; Общая характеристика лекарственного препарата Эрлеада (01.09.2023). Доступно по: http://eec.eaeunion.org/; https://oncourology.abvpress.ru/oncur/article/view/1876
-
2Academic Journal
Συγγραφείς: V. B. Matveev, B. Ya. Alekseev, B. Sh. Kamolov, A. S. Markova, В. Б. Матвеев, Б. Я. Алексеев, Б. Ш. Камолов, А. С. Маркова
Πηγή: Cancer Urology; Том 17, № 2 (2021); 83-92 ; Онкоурология; Том 17, № 2 (2021); 83-92 ; 1996-1812 ; 1726-9776
Θεματικοί όροι: неинтервенционное исследование, androgen deprivation therapy, hormone therapy, luteinizing hormone-releasing hormone agonists, routine clinical practice, non-interventional study, андроген-депривационная терапия, гормональная терапия, агонист лютеинизирующего гормона рилизинг-гормона, рутинная клиническая практика
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1466/1276; Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 250 с.; Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старин-ского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 236 с.; Mottet N., Cornford P., van den Bergh R.C.N. et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology, 2021. P. 212.; Seidenfeld J., Samson D.J., Hasselblad V. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566-77. DOI:10.7326/0003-4819-132-7200004040-00009; Rick F.G., Schally A.V. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer. Urol Oncol 2015;33(6):270-4. DOI:10.1016/j.urolonc.2014.11.006.; Schally A.V., Block N.L., Rick F.G. Discovery of LHRH and development of LHRH analogs for prostate cancer treatment. Prostate 2017;77(9):1036-54. DOI:10.1002/pros.23360.; Liu S.V., Liu S., Pinski J. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Expert Opin Investig Drugs 2011;20(6):769-78. DOI:10.1517/13543784.2011.574611.; Perez-Marrero R., Tyler R.C. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2):447-57. DOI:10.1517/14656566.5.2.447.; Chu F.M., Jayson M., Dineen M.K. et al. A clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168(3):1199-203. DOI:10.1097/01.ju.0000023895.95963.1b.; Oefelein M.G., Feng A., Scolieri M.J. et al. Reassessment of the definition of castratelevels of testosterone: implications for clinical decision making. Urology 2000;56(6):1021-4. DOI:10.1016/s0090-4295(00)00793-7.; Матвеев В.Б., Маркова А.С. Финальные результаты проспективной многоцентровой наблюдательной программы RU-EGD-NI-001 по оценке эффективности и переносимости 6-месячной депо-формы Элигарда 45 мг у больных распространенным раком предстательной железы в рутинной клинической практике российских онкоурологов. Онкоурология 2017;13(2):79-86. DOI:10.17650/1726-9776-2017-13-2-79-86.; Tunn U.W. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urology 2011;11:15. DOI:10.1186/1471-2490-11-15.; Montorsi F., Tomlinson P. Which luteinising hormone-releasing hormone agonist injection schedule do men with prostate cancer prefer? Results of a European patient survey. Eur Urol 2015;67(1):177-9. DOI:10.1016/j.eururo.2014.08.055.; Рак предстательной железы. Клинические рекомендации. Ассоциация онкологов России, 2020.; Рак предстательной железы. Клинические рекомендации. Министерство здравоохранения Российской Федерации, 2021.; Klotz L., O'Callaghan C., Ding K. et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 2015;33(10):1151-6. DOI:10.1200/JCO.2014.58.2973.; https://oncourology.abvpress.ru/oncur/article/view/1466
-
3Academic Journal
Συγγραφείς: V. B. Matveev, A. S. Markova, В. Б. Матвеев, А. С. Маркова
Πηγή: Cancer Urology; Том 13, № 2 (2017); 79-86 ; Онкоурология; Том 13, № 2 (2017); 79-86 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2017-13-2
Θεματικοί όροι: агонист лютеинизирующего гормона рилизинг-гормона, leuproreline acetate, Eligard, non-interventional study, testosterone, prostatic specific antigen, quality of life, luteinizing hormone releasing hormone agonist, лейпрорелина ацетат, Элигард, неинтервенционное исследование, тестостерон, простатический специфический антиген, качество жизни
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/689/662; Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 250 с. [Malignant tumors in Russia in 2015 (morbidity and fatality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2017. 250 p. (In Russ.)].; Состояние онкологической помощи населению России в 2016 году. Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 236 с. [State of oncological care in Russia in 2015. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2016. 236 p. (In Russ.)].; Guidelines on Prostate Cancer. European Association of Urology (EAU). 2017. 146 p.; Hedlund P.O., Damber J.E., Hagerman I. et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008;42(3):220–9. DOI:10.1080/00365590801943274. PMID: 18432528.; Seidenfeld J., Samson D.J., Hasselblad V. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566–77. PMID: 10744594.; Klotz L., Boccon-Gibod L., Shore N.D. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11):1531–8. DOI:10.1111/j.1464-410X.2008.08183.x. PMID: 19035858.; Guidelines on Prostate Cancer. European Association of Urology (EAU). 2015. 137 p.; Perez-Marreno R., Chu F.M., Gleason D. et al. A six-month, open-label study assessing a new formulation of leuprolide 7,5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002;24(11):1902–14. PMID: 12501882.; Perez-Marreno R., Tyler R.C. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2):447–57. DOI:10.1517/14656566.5.2.447. PMID: 14996640.; Chu F.M., Jayson M., Dineen M.K. et al. A clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168(3):1199–203. DOI:10.1097/01.ju.0000023895.95963.1b. PMID: 12187267.; Crawford E.D., Sartor O., Chu F. et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175(2):533–6. DOI:10.1016/S0022-5347(05)00161-8. PMID: 16406989.; Kunath F., Grobe H.R., Rücker G. et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormonereleasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev 2014;6:CD009266. DOI:10.1002/14651858.CD009266.pub2. PMID: 24979481.; Montorsi F., Tomlinson P. Which luteinising hormone-releasing hormone agonist injection schedule do men with prostate cancer prefer? Results of a European patient survey. Eur Urol 2015;67(1):177–9. DOI:10.1016/j.eururo.2014.08.055. PMID: 25220374.; Tunn U.W. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urology 2011;11:15. DOI:10.1186/1471-2490-11-15. PMID: 21801354. Available at: http://www.biomedcentral. com/1471-2490/11/15.; Braeckman J., Michielsen D. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard®/Depo-Eligard®) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study. Arch Med Sci 2014;10(3): 477–83. DOI:10.5114/aoms.2014.43743. PMID: 25097577.; https://oncourology.abvpress.ru/oncur/article/view/689